Biologic therapy in psoriasis

Indian Journal of Dermatology, Venereology and Leprology

Volumn 72, Issue 4, 2006, Pages 256-265

  Dogra, Alka ^a   Sachdeva, Silonie ^a  

^a DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; DENILEUKIN DIFTITOX; EFALIZUMAB; ETANERCEPT; ETRETIN; GALIXIMAB; IMMUNOLOGIC AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 4; METHOTREXATE; OKT 4; ONERCEPT; PLACEBO; SIPLIZUMAB; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; AUTOIMMUNE HEMOLYTIC ANEMIA; CHILL; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; INFECTION; INJECTION SITE CONTUSION; INJECTION SITE EDEMA; INJECTION SITE REACTION; LIVER DYSFUNCTION; MYALGIA; NAUSEA; PATHOGENESIS; PATIENT MONITORING; PHOTOTHERAPY; PSORIASIS; PUVA; REVIEW; RHINITIS; SEPSIS; SIDE EFFECT; T LYMPHOCYTE; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 33746891236     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.26712     Document Type: Review

References (44)

1. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, et al. British association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486-97.
2. Mehlis S, Gordon KB. From laboratory to clinic: Rationale for biologic therapy. Dermatol Clin 2004;22:371-7.
3. Kormeili T, Lowe NJ, Yamuchi PS. Psoriasis: Immunopathogenesis and evolving immunomodulators and systemic therapies; U.S experiences. Br J Dermatol 2004;151:3-15.
4. Sauder DN, Mamelak AJ. Understanding the new clinical landscape for psoriasis: A comparative review of biologics. J Cutan Med Surg 2004;8:205-12.
5. Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: Role of biologic agents. J Manag Care Pharm 2004;10:318-25.
6. Lowes MA, Lew W, Krueger JG. Current concepts in the immunopathogenesis of psoriasis. Dermatol Clin 2004;22:349-69.
7. Joshi R. Immunopathogenesis of psoriasis. Indian J Dermatol Venerol Leprol 2004;70:10-2.
8. Thappa DV, Laxmisha C. Immunomodulators in the treatment of psoriasis. Indian J Dermatol Venerol Leprol 2004;70:1-9.
9. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004;151:3-17.
10. Koo J, Khera P. Update on the mechanisms and efficacy of biological therapies for psoriasis. J Dermatol Sci 2005;38:75-87.
11. Krueger GG. Current concepts and review of alefacept in the treatment of psoriasis. Dermatol Clin 2004;22:407-26.
12. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-33.
13. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE, et al. Alefacept clinical study group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27.
14. Myers W, Christian L, Gottlieb AB. Treatment of palmoplantar psoriasis with intramuscular alefacept. J Am Acad Dermatol 2005;5:127-9.
15. Menter A, Cather JC, Baker D, Farber HF, Lebwohi M, Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006;54:61-3.
16. Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD, et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol 2003;49:816-25.
17. Leonardi CL. Current concepts and review of efalizumab in the treatment of psoriasis. Dermatol Clin 2004;22:427-35.
18. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;21:2004-13.
19. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized control trial. JAMA 2003;23:3073-80.
20. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trials. J Am Acad Dermatol 2005; 52:425-33.
21. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31-8.
22. Goldsmith DR, Wagstaff AJ. Etanercept: A review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 2005;6:121-36.
23. Yamuchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: Practical considerations on monotherapy, combination therapy and safety. Dermatol Clin 2004;22:449-59.
24. Mease PJ, Goffe BS, Metz J, Vander SA, Finck B, Burge DJ. Etanercept in treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 2000;356:385-90.
25. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32.
26. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
27. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global Phase III randomized control trial of etanercept in psoriasis: Safety, efficacy and effect of dose reduction. Br J Dermatol 2005;152:1304-12.
28. Winterfield L, Menter A. Psoriasis and its treatment with infliximab-mediated tumour necrosis factor a blockade. Dermatol Clin 2004; 22: 437-44.
29. Mastroianni A, Minutilli E, Mussi A, Bordignon V. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 2005;153:531-6.
30. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab montherapy for plaque type psoriasis: A randomized trial. Lancet 2001;35:1842-7.
31. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque type psoriasis: A randomized, double-blind, placebo controlled trial. J Am Acad Dermatol 2004;51:534-42.
32. Zargari O. Sustained effects of low dose infliximab in combination with methotrexate in the management of chronic recalcitrant psoriasis. Dermatol Online J 2005;11:21.
33. Scheinfeld N. Adalimumab (HUMIRA): A review. J Drugs Dermatol 2003;2:375-7.
34. Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickloff BJ. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005;153:945-53.
35. Chew AL, Bennett A, Smith CH, Barker J, Kirkham B. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 2004;151:492-6.
36. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
37. Nikas SN, Drosos AA. Onercept. Serono. Curr Opin Investig Drugs 2003;4:1369-76.
38. Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double blind, phase II multicenter trial. J Am Acad Dermatol 1998;3:938-44.
39. Owen CM, Harrison PV. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol 2000;25:195-7.
40. Salim A, Emerson RM, Dalziel KL. Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker). Br J Dermatol 2000;143:1121-2.
41. Wohlrab J, Fischer M, Taube KM, Marsch WC. Treatment of recalcitrant psoriasis with daclizumab. Br J Dermatol 2001;144:209-10.
42. Dichmann S, Mrowietz U, Schopf E, Norgauer J. Humanized monoclonal anti-CD25 antibody as a novel therapeutic option in HIV-associated psoriatic erythroderma. J Am Acad Dermatol 2002;47:635-6.
43. Sukal SA, Nadiminti L, Granstein RD. Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol 2006;54:160-4.
44. Scheinfeld N. Adalimumab: A review of side effects. Exp Opin Drug Saf 2005;4:637-41.